Physiologically based pharmacokinetic modelling to determine the impact of CYP2B6 genotype on efavirenz exposure in children, mothers and breastfeeding infants.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical pharmacology and therapeutics"
DOI: 10.1002/cpt.2912
Abstract: The antiretroviral drug efavirenz remains widely used in children and mothers during breastfeeding in tuberculosis-endemic areas. Evaluating the safety of efavirenz during breastfeeding requires an understanding of its pharmacokinetics in breast milk, its exposure in… read more here.
Keywords: efavirenz; mothers breastfeeding; breastfeeding infants; cyp2b6 ... See more keywords
Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of hepatology"
DOI: 10.1016/j.jhep.2018.12.038
Abstract: BACKGROUND & AIMS The most prescribed non-nucleoside reverse transcriptase inhibitor, efavirenz, has been associated with elevated risk of dyslipidemia and hepatic steatosis in HIV-infected patients but the underlying mechanisms remain elusive. Herein, we investigated the… read more here.
Keywords: hepatic steatosis; efavirenz; non nucleoside; pxr ... See more keywords
Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of pharmacological sciences"
DOI: 10.1016/j.jphs.2020.07.013
Abstract: Patients living with HIV in malarial endemic regions may experience clinically significant drug interaction between antiretroviral and antimalarial drugs. Effects of nevirapine (NVP), efavirenz (EFV) and lopinavir/ritonavir (LPVr) on lumefantrine (LM) therapeutic concentrations and toxicity… read more here.
Keywords: living hiv; efavirenz; toxicity; lopinavir ritonavir ... See more keywords
Thermal Behavior and Slow Relaxation Dynamics in Amorphous Efavirenz: A Study by DSC, XRPD, TSDC, and DRS.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of pharmaceutical sciences"
DOI: 10.1016/j.xphs.2018.10.050
Abstract: The analysis of the thermal behavior of efavirenz showed a high glass-forming ability and good glass stability of this glass-forming liquid at room temperature. No polymorphic forms were formed either by cold crystallization or by… read more here.
Keywords: drs; relaxation; thermal behavior; efavirenz ... See more keywords
The antiviral drug efavirenz reduces biofilm formation and hemolysis by Staphylococcus aureus.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of medical microbiology"
DOI: 10.1099/jmm.0.001433
Abstract: Introduction. Biofilm formation and hemolysis are closely related to the pathogenicity of Staphylococcus aureus.Hypothesis/Gap Statement. Strategies that reduce the mortality of S. aureus infections may involve novel antimicrobials and/or drugs that decrease S. aureus virulence,… read more here.
Keywords: virulence; efavirenz; biofilm formation; hemolysis ... See more keywords
Efavirenz-Induced Vanishing Bile Duct Syndrome: A Case Report
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Pharmacy Practice"
DOI: 10.1177/0897190019868358
Abstract: Background: Efavirenz (Sustiva®) is used for the treatment of human immunodeficiency virus (HIV) type 1 infection. Hepatoxicity is a known potential adverse drug event with efavirenz; however, to our knowledge, vanishing bile duct syndrome (VBDS),… read more here.
Keywords: efavirenz; case; bile duct; efavirenz induced ... See more keywords
Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate)
Sign Up to like & getrecommendations! Published in 2018 at "PLoS ONE"
DOI: 10.1371/journal.pone.0202706
Abstract: Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor used in first-line combination antiretroviral therapy (cART). It is usually administered with nucleoside reverse transcriptase inhibitors (NRTI), many of which are substrates of OCT uptake solute carriers… read more here.
Keywords: efavirenz; mate; mate mate; lamivudine ... See more keywords
Efavirenz: History, Development and Future
Sign Up to like & getrecommendations! Published in 2022 at "Biomolecules"
DOI: 10.3390/biom13010088
Abstract: Efavirenz (Sustiva®) is a first-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat human immunodeficiency virus (HIV) type 1 infection or to prevent the spread of HIV. In 1998, the FDA authorized efavirenz for the… read more here.
Keywords: efavirenz; hiv; efavirenz history; development future ... See more keywords
The Antiviral Drug Efavirenz in Breast Cancer Stem Cell Therapy
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers13246232
Abstract: Simple Summary Cancer stem cells (CSCs) are responsible for tumour initiation, chemo- and radiotherapy resistance and cancer recurrence. CSCs display plasticity that enables them to alter their phenotype and function making them challenging to eliminate.… read more here.
Keywords: cancer; breast; breast cancer; efavirenz ... See more keywords
Cytotoxic effect of Efavirenz in BxPC-3 pancreatic cancer cells is based on oxidative stress and is synergistic with ionizing radiation
Sign Up to like & getrecommendations! Published in 2018 at "Oncology Letters"
DOI: 10.3892/ol.2017.7523
Abstract: The non-nucleoside reverse transcriptase inhibitor (NNRTI) Efavirenz is frequently used in human immunodeficiency virus treatment, but also efficient against cancer in mouse models. Its radiosensitizing effect makes it a promising drug for combination with radiotherapy.… read more here.
Keywords: efavirenz; effect; cancer cells; cancer ... See more keywords